MARKET

FBIO

FBIO

Fortress Biotech
NASDAQ

Real-time Quotes | Nasdaq Last Sale

4.310
+0.010
+0.23%
Opening 10:52 04/23 EDT
OPEN
4.330
PREV CLOSE
4.300
HIGH
4.440
LOW
4.280
VOLUME
253.41K
TURNOVER
--
52 WEEK HIGH
6.10
52 WEEK LOW
1.890
MARKET CAP
409.04M
P/E (TTM)
-6.5331
1D
5D
1M
3M
1Y
5Y
Mustang Bio to Participate in Chardan’s 5th Annual Genetic Medicines Manufacturing Summit
WORCESTER, Mass., April 21, 2021 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematolog...
GlobeNewswire · 2d ago
Dendritic Cell Therapy Market Trends, Share, Size, Growth, Opportunity and Forecast 2025 | Says Kenneth Research
Apr 21, 2021 (AmericaNewsHour) -- Kenneth Research recently added a report on 'Dendritic Cell Therapy Market' in its database of market research reports...
AmericaNewsHour · 2d ago
Roth Capital Sticks to Their Buy Rating for Fortress Biotech (FBIO)
Roth Capital analyst Scott Henry maintained a Buy rating on Fortress Biotech (FBIO) today and set a price target of $5.00. The company's shares closed
SmarterAnalyst · 2d ago
DJ Fortress Biotech Price Target Raised to $5.00/Share From $4.50 by Roth Capital
Dow Jones · 3d ago
DJ Fortress Biotech Is Maintained at Buy by Roth Capital
Dow Jones · 3d ago
--Roth Capital Adjusts Price Target on Fortress Biotech to $5 From $4.50, Maintains Buy Rating
MT Newswires · 3d ago
Natural Killer Cells Therapeutics Market 2021 | Top Leading Countries, Companies, Size, Revenue, Consumption, Drivers, Trends, Challenges and Global Forecast to 2026
Apr 20, 2021 (The Expresswire) -- Global “Natural Killer Cells Therapeutics Market” research report provides the newest industry data and industry future...
The Express Wire · 3d ago
Avenue Makes Way Down at Open
Apr 19, 2021 (Baystreet.ca via COMTEX) -- Avenue Therapeutics, Inc. (NASDAQ: ATXI) saw its shares slide early Monday, on word Washington was still hemming...
Baystreet.ca · 4d ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of FBIO. Analyze the recent business situations of Fortress Biotech through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 6 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average FBIO stock price target is 10.33 with a high estimate of 24.00 and a low estimate of 5.00.
EPS
Institutional Holdings
Institutions: 116
Institutional Holdings: 33.08M
% Owned: 34.85%
Shares Outstanding: 94.91M
TypeInstitutionsShares
Increased
30
2.55M
New
19
698.22K
Decreased
22
2.00M
Sold Out
9
160.85K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+0.08%
Pharmaceuticals & Medical Research
+0.47%
Key Executives
Chairman/President/Chief Executive Officer/Executive Director
Lindsay Rosenwald
Vice Chairman/Director
Eric Rowinsky
Chief Financial Officer/Treasurer/Secretary
Robyn Hunter
Corporate Executive/Executive Director
Michael Weiss
Senior Vice President
George Avgerinos
Independent Director
Jimmie Harvey
Independent Director
Malcolm Hoenlein
Independent Director
Dov Klein
Independent Director
J. Jay Lobell
Independent Director
Kevin Lorenz
No Data
About FBIO
Fortress Biotech, Inc.(Fortress) is a biopharmaceutical company that acquires, develops and commercializes novel pharmaceutical and biotechnology products. Fortress develops and commercializes products both within Fortress and through certain of its subsidiary companies. Fortress has 11 operating subsidiaries that include: 4 commercial stage programs, 25 development stage programs, targeting 6 therapeutic areas: Immuno-oncology, Hematology, Gene Therapy, Pain Management, Rare Diseases and Dermatology. In addition to its internal development programs, Fortress leverages its biopharmaceutical business expertise and drug development capabilities and provides funding and management services to help the Fortress Companies. Fortress subsidiaries include Aevitas Therapeutics, Avenue Therapeutics, Caelum Biosciences, Cellvation, Inc., Checkpoint Therapeutics, Cyprium Therapeutics, Helocyte, Inc., Journey Medical Corporation, Mustang Bio and Tamid Bio, Inc.

Webull offers kinds of Fortress Biotech Inc stock information, including NASDAQ:FBIO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, FBIO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading FBIO stock methods without spending real money on the virtual paper trading platform.